PMID- 28179315
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20170227
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 2
DP  - 2017 Feb
TI  - Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis 
      of CD8(+) Tumour-infiltrating Lymphocytes and Other Biomarkers in Cancer of 
      Unknown Primary in the Head and Neck Region.
PG  - 665-673
AB  - BACKGROUND: Human papillomavirus (HPV) is a favourable prognostic factor in 
      oropharyngeal cancer. Moreover, we and others reported that HPV-positive cancer 
      of unknown primary in the head and neck region (HNCUP) has better outcome than 
      HPV-negative HNCUP. However, not all studies concord. Here, our previous finding 
      was investigated in a new cohort and additional biomarkers were analyzed. 
      MATERIALS AND METHODS: A total of 19 HNCUPs diagnosed 2008-2013 were analyzed for 
      HPV DNA by polymerase chain reaction assay (PCR) and p16 by immunohistochemistry 
      (IHC). Thereafter, 69 HNCUPs diagnosed between 2000-2013 were analyzed for HPV16 
      mRNA by PCR (if HPV16DNA-positive) and cluster of differentiation 8 positive 
      (CD8(+)) tumour-infiltrating lymphocytes (TILs) and human leukocyte antigen (HLA) 
      class I-expression using IHC. RESULTS: HPV DNA, alone and in combination with p16 
      overexpression, was validated as a favourable prognostic factor in HNCUP. HPV16 
      mRNA was present in most HPV16 DNA-positive cases, confirming HPV-driven 
      carcinogenesis in HNCUP. High CD8(+) TIL counts indicated favourable prognosis. 
      CONCLUSION: HPV status is useful for the management of patients with HNCUP and 
      the role of CD8(+) TILs should be further explored.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Sivars, Lars
AU  - Sivars L
AD  - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden 
      Lars.Sivars@ki.se Tina.Dalianis@ki.se.
FAU - Landin, David
AU  - Landin D
AD  - Department of Clinical Science, Intervention and Technology, Division of ENT 
      Diseases, Karolinska Institute, Stockholm, Sweden.
FAU - Grun, Nathalie
AU  - Grun N
AD  - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
FAU - Vlastos, Andrea
AU  - Vlastos A
AD  - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
AD  - Department of Clinical Science, Intervention and Technology, Division of ENT 
      Diseases, Karolinska Institute, Stockholm, Sweden.
FAU - Marklund, Linda
AU  - Marklund L
AD  - Department of Clinical Science, Intervention and Technology, Division of ENT 
      Diseases, Karolinska Institute, Stockholm, Sweden.
FAU - Nordemar, Sushma
AU  - Nordemar S
AD  - Department of Clinical Science, Intervention and Technology, Division of ENT 
      Diseases, Karolinska Institute, Stockholm, Sweden.
FAU - Ramqvist, Torbjorn
AU  - Ramqvist T
AD  - Department of Clinical Science, Intervention and Technology, Division of ENT 
      Diseases, Karolinska Institute, Stockholm, Sweden.
FAU - Munck-Wikland, Eva
AU  - Munck-Wikland E
AD  - Department of Clinical Science, Intervention and Technology, Division of ENT 
      Diseases, Karolinska Institute, Stockholm, Sweden.
FAU - Nasman, Anders
AU  - Nasman A
AD  - Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
AD  - Department of Clinical Pathology, Karolinska University Hospital, Stockholm, 
      Sweden.
FAU - Dalianis, Tina
AU  - Dalianis T
AD  - Department of Clinical Science, Intervention and Technology, Division of ENT 
      Diseases, Karolinska Institute, Stockholm, Sweden Lars.Sivars@ki.se 
      Tina.Dalianis@ki.se.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cyclin-Dependent Kinase Inhibitor p16/immunology/metabolism
MH  - DNA, Viral/genetics/immunology
MH  - Female
MH  - Head and Neck Neoplasms/diagnosis/*immunology/virology
MH  - Host-Pathogen Interactions/immunology
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasms, Unknown Primary/diagnosis/*immunology/virology
MH  - Papillomaviridae/genetics/immunology/physiology
MH  - Papillomavirus Infections/*immunology/virology
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - Human papillomavirus
OT  - head and neck cancer
OT  - lymphocytes
OT  - neoplasms
OT  - oropharyngeal cancer
OT  - tumor-infiltrating
OT  - unknown primary
EDAT- 2017/02/10 06:00
MHDA- 2017/02/28 06:00
CRDT- 2017/02/10 06:00
PHST- 2016/12/08 00:00 [received]
PHST- 2017/01/17 00:00 [revised]
PHST- 2017/01/18 00:00 [accepted]
PHST- 2017/02/10 06:00 [entrez]
PHST- 2017/02/10 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - 37/2/665 [pii]
AID - 10.21873/anticanres.11362 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Feb;37(2):665-673. doi: 10.21873/anticanres.11362.